Status:
TERMINATED
Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Obesity
Insulin Resistance
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to learn more about how insulin resistance (inability to process glucose correctly resulting in mildly elevated glucose levels) affects the hormone ghrelin.
Detailed Description
Insulin resistance suppresses fasting ghrelin levels and impairs postprandial ghrelin suppression. Improved insulin sensitivity with a thiazolidinedione will raise ghrelin levels, enhance meal-related...
Eligibility Criteria
Inclusion
- Age 18 to 80, weight stable for at least 3 months
- At lifetime maximal body weight and impaired glucose tolerance (ICT) by the World Health ORganization criteria:
- fasting plasma glucose level of 100- 125mg/dL or
- plasma glucose level between 140 to 149mg/dL following a 75gram oral glucose load
Exclusion
- Actively losing weight
- Smokers
- Alcohol consumption \> 2 drinks/day
- Prescription drug use
- Recreational drug use
- Type 2 Diabetes
- Conditions that contraindicate treatment with pioglitazone such as CHF, impaired liver or kidney function or known sensitivity to pioglitazone
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00843791
Start Date
February 1 2009
End Date
May 1 2011
Last Update
January 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239